Advertisement
Letter to the Editor| Volume 102, P138-139, August 2022

Download started.

Ok

Disease phenotype and outcomes of very early-onset inflammatory bowel disease

  • Valeria Dipasquale
    Affiliations
    Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University Hospital of Messina, Messina, Italy
    Search for articles by this author
  • Giovanna Lo Presti
    Affiliations
    Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University Hospital of Messina, Messina, Italy
    Search for articles by this author
  • Claudio Romano
    Correspondence
    Corresponding author at: Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University Hospital of Messina, Via Consolare Valeria 1, Messina, 98124, Italy
    Affiliations
    Pediatric Gastroenterology and Cystic Fibrosis Unit, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University Hospital of Messina, Messina, Italy
    Search for articles by this author
Published:May 06, 2022DOI:https://doi.org/10.1016/j.ejim.2022.05.001
Disease phenotype and outcomes of very early-onset inflammatory bowel disease
Previous ArticleGeneral practitioner agreement and adherence to the Swiss Choosing wisely top 5 list: A cross-sectional survey
      Dear Editor,
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Vernier-Massouille G
        • Balde M
        • Salleron J
        • et al.
        Natural history of pediatric Crohn’s disease: A population-based cohort study.
        Gastroenterology. 2008; 135: 1106-1113
        View in Article
        • Benchimol EI
        • Bernstein CN
        • Bitton A
        • et al.
        Trends in epidemiology of pediatric inflammatory bowel disease in Canada: Distributed network analysis of multiple population based provincial health administrative databases.
        Am J Gastroenterol. 2017; 112: 1120-1134
        View in Article
        • Kelsen JR
        • Sullivan KE
        • Rabizadeh S
        • et al.
        North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the evaluation and management for patients with very early-onset inflammatory bowel disease.
        J Pediatr Gastroenterol Nutr. 2020; 70: 389-403
        View in Article
        • Bramuzzo M
        • Arrigo S
        • Romano C
        • et al.
        Efficacy and safety of infliximab in very early onset inflammatory bowel disease: A national comparative retrospective study.
        United European Gastroenterol J. 2019; 7: 759-766
        View in Article
        • Romeo AC
        • Ventimiglia M
        • Dipasquale V
        • et al.
        Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian network.
        Clin Res Hepatol Gastroenterol. 2020; 44: 223-229
        View in Article
        • Gupta N
        • Bostrom AG
        • Kirschner BS
        • et al.
        Presentation and disease course in early- compared to later-onset pediatric Crohn's disease.
        Am J Gastroenterol. 2008; 103: 2092-2098
        View in Article
        • Turner D
        • Ruemmele FM
        • Orlanski-Meyer E
        • et al.
        Management of paediatric ulcerative colitis, part 1: Ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
        J Pediatr Gastroenterol Nutr. 2018; 67: 257-291
        View in Article
        • Dotan I
        • Ron Y
        • Yanai H
        • et al.
        Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study.
        Inflamm Bowel Dis. 2014; 20: 2247-2259
        View in Article
        • Jongsma MME
        • Winter DA
        • Huynh HQ
        • et al.
        Infliximab in young paediatric IBD patients: It is all about the dosing.
        Eur J Pediatr. 2020; 179: 1935-1944
        View in Article
        • van Rheenen PF
        • Aloi M
        • Assa A
        • et al.
        The medical management of paediatric Crohn's disease: An ECCO-ESPGHAN guideline update.
        J Crohns Colitis. 2020; : jjaa161
        View in Article

      Article info

      Publication history

      Published online: May 06, 2022
      Accepted: May 2, 2022
      Received in revised form: April 25, 2022
      Received: April 2, 2022

      Identification

      DOI: https://doi.org/10.1016/j.ejim.2022.05.001

      Copyright

      © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX